Utama › Limfoma
Kajian klinikal Limfoma sedang mengambil peserta di AS
142 kajian untuk Limfoma sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Houston, TX34 kajian
- Boston, MA33 kajian
- New York City, NY33 kajian
- Washington, DC23 kajian
- Baldwin Park, CA21 kajian
- Chicago, IL20 kajian
- Durham, NC17 kajian
- St. Louis, MO15 kajian
- Philadelphia, PA15 kajian
- Cleveland, OH14 kajian
- Edison, NJ12 kajian
- Atlanta, GA12 kajian
- Seattle, WA12 kajian
- Salt Lake City, UT11 kajian
- Rochester, MN11 kajian
- Columbus, OH11 kajian
- Nashville, TN11 kajian
- Miami, FL11 kajian
- Pittsburgh, PA10 kajian
- Los Angeles, CA10 kajian
- Dallas, TX10 kajian
- Queens, NY10 kajian
- Mountain View, CA9 kajian
- Denver, CO9 kajian
- Greenburgh, NY9 kajian
- Portland, OR9 kajian
- Milwaukee, WI9 kajian
- Aurora, CO8 kajian
- Birmingham, AL8 kajian
- East Norwalk, CT8 kajian
- Staten Island, NY8 kajian
- Cincinnati, OH8 kajian
- San Antonio, TX7 kajian
- Tampa, FL7 kajian
- New Haven, CT7 kajian
- New Rochelle, NY7 kajian
- Omaha, NE7 kajian
- Phoenix, AZ7 kajian
- Kansas City, MO6 kajian
- Buffalo, NY6 kajian
Mengikut negeri
- Alabama9 kajian
- Arizona11 kajian
- Arkansas3 kajian
- California40 kajian
- Colorado16 kajian
- Connecticut7 kajian
- Florida25 kajian
- Georgia16 kajian
- Illinois23 kajian
- Indiana6 kajian
- Iowa6 kajian
- Kansas7 kajian
- Kentucky5 kajian
- Maryland21 kajian
- Massachusetts33 kajian
- Michigan12 kajian
- Minnesota14 kajian
- Missouri17 kajian
- Nebraska7 kajian
- New Jersey18 kajian
- New York42 kajian
- North Carolina22 kajian
- Ohio29 kajian
- Oklahoma4 kajian
- Oregon9 kajian
- Pennsylvania24 kajian
- South Carolina4 kajian
- Tennessee15 kajian
- Texas45 kajian
- Utah14 kajian
- Virginia10 kajian
- Washington12 kajian
- Wilayah Columbia7 kajian
- Wisconsin12 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Mengambil pesertaFasa 1
Umur 12 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT02917083Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT03258567Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Mengambil pesertaKajian pemerhatian
Umur 3 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT01441089Rutgers University Study of the Genetics of Blood Cancers
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 hingga 110 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07714044T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Mengambil pesertaKajian pemerhatian
Umur 0 hingga 38 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 3 hingga 39 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT05442515A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07192471A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07015242A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Mengambil pesertaFasa 2
1 Month – 17 Years · Semua jantina · Dikemas kini 30 Sep 2026 · NCT04570423Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07583810Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 120 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT00006518A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07013435Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07014293Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT03418038Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 110 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT00923507Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Mengambil pesertaFasa 1/2
Umur 18 hingga 120 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT03223610A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Mengambil pesertaFasa 1/2
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04094610Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Mengambil pesertaFasa 1
24 Months – 18 Years · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06441331Epco, Zanu, Ritux for R/R FL or MZL
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06563596Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Mengambil pesertaFasa awal 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06398457Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT02974647CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Mengambil pesertaFasa 2
Umur 18 hingga 99 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT04083495Precise Oncology Interventions in Nutrition and Training (OnPoint)
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06534918Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT04301076Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.